Adebambo O. Ojuri, M.D.
Specialist
8110 Airport Blvd, Second Floor
Los Angeles, CA 90045
Who else practices at this address →
Los Angeles County includes primary care (7% of residents) and mental health (13% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 42
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 224
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
- Specialist primary
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- West Gastroenterology Medical Group (4 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 224
- Services billed
- 512
- Patients’ average age
- 68
| Service | Times | Patients |
|---|---|---|
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 210 | 194 |
| Biopsy of large bowel using a flexible endoscope | 112 | 111 |
| New patient office or other outpatient visit, 45-59 minutes | 92 | 92 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 89 | 89 |
| Established patient office or other outpatient visit, 30-39 minutes | 87 | 70 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 36 | 35 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Pantoprazole Sodium Other prescribers in Los Angeles, CA | 83 |
| Linzess (linaclotide) Other prescribers in Los Angeles, CA | 32 |
| Famotidine Other prescribers in Los Angeles, CA | 29 |
| Plenvu (peg3350/sod sul/nacl/kcl/asb/c) | 28 |
| Gavilyte-G (peg3350/sod sulf,bicarb,cl/kcl) Other prescribers in Los Angeles, CA | 23 |
| Peg-3350 And Electrolytes (peg3350/sod sulf,bicarb,cl/kcl) Other prescribers in Los Angeles, CA | 18 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 9 companies reported 57 payments worth $1,188 in total to this clinician.
| Ardelyx, Inc. | $360 |
|---|---|
| Madrigal Pharmaceuticals | $326 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $182 |
| AbbVie Inc. | $112 |
| Pfizer Inc. | $71.61 |
| Janssen Biotech, Inc. | $68.08 |
| Celltrion USA Inc. | $34.47 |
| Intercept Pharmaceuticals, Inc. | $18.33 |
| Food and Beverage | $1,188 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $22,718 in research payments for these studies, mostly to the institutions running them.
- A study of TAK-062 in treatment of active celiac disease in participants attempting a gluten-free diet
Takeda Pharmaceuticals U.S.A., Inc. - An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical Practice
E.r. Squibb & Sons, L.l.c. · Terminated · NCT05369832
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.